15 Stocks Set to Explode in 2026

Page 11 of 13

3. Vaxcyte, Inc. (NASDAQ:PCVX)

Number of Hedge Fund Holders: 44

Upside Potential: 137.00%

With significant upside potential and hedge fund interest, Vaxcyte, Inc. (NASDAQ:PCVX) secured a spot on our list of the 15 stocks set to explode in 2026.

On November 5, 2025, TD Cowen analyst Tara Bancroft reiterated her “Buy” rating on Vaxcyte, Inc. (NASDAQ:PCVX) with a $50 price target.

The analyst cited positive Phase II data from the company’s VAX-24 infant vaccine trials. With the VAX-24 meeting non-inferiority criteria for most serotypes, the study demonstrated robust immune responses and a dose-dependent increase in immunogenicity, with no evidence of carrier suppression. With Phase III results expected in 2026, she believes the data reinforce Vaxcyte, Inc. (NASDAQ:PCVX)’s optimized dosing approach for its VAX-31 program. Moreover, she believes the vaccine’s competitive edge over Prevnar is further enhanced by its potential to deliver improved titers when co-administered with a flu vaccine.

On the other hand, on November 4, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) released its Q3 2025 results. Closing the quarter with $2.7 billion in cash, the company noted consistent Phase II results for VAX-24 in infants. On that note, Vaxcyte reaffirmed its plans to initiate the VAX-31 critical adult trial in December.

Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company, develops high-fidelity conjugate vaccines. It helps prevent invasive pneumococcal disease, with its lead candidates, VAX-31 and VAX-24, aiming to provide broad-spectrum bacterial protection.

Page 11 of 13